Drug Type Small molecule drug |
Synonyms (±)-MRJF 22, (±)-MRJF22 |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors), σ1 receptor antagonists(Sigma opioid receptor antagonists), σ2 receptor agonists(Sigma-2 receptor agonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC29H39ClFNO3 |
InChIKeyZMMTZQWVQFDIBG-UHFFFAOYSA-N |
CAS Registry2044017-78-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Proliferative retinopathy with diabetes mellitus | Preclinical | IT | 25 Oct 2016 | |
Wet age-related macular degeneration | Preclinical | IT | 25 Oct 2016 |